Dense and dangerous: The tissue plasminogen activator-resistant fibrinolysis shutdown phenotype is due to abnormal fibrin polymerization.


Journal

The journal of trauma and acute care surgery
ISSN: 2163-0763
Titre abrégé: J Trauma Acute Care Surg
Pays: United States
ID NLM: 101570622

Informations de publication

Date de publication:
02 2020
Historique:
entrez: 31 1 2020
pubmed: 31 1 2020
medline: 12 8 2020
Statut: ppublish

Résumé

Both hyperfibrinolysis and fibrinolysis shutdown can occur after severe trauma. The subgroup of trauma patients with fibrinolysis shutdown resistant to tissue plasminogen activator (t-PA)-mediated fibrinolysis have increased mortality. Fibrin polymerization and structure may influence fibrinolysis subgroups in trauma, but fibrin architecture has not been characterized in acutely injured subjects. We hypothesized that fibrin polymerization measured in situ will correlate with fibrinolysis subgroups. Blood samples were collected from trauma patients and noninjured controls. We selected samples across a range of fibrinolysis phenotypes (shutdown, physiologic, hyperfibrinolysis) and t-PA sensitivities (sensitive, physiologic, resistant) determined by thrombelastography. Plasma clots were created in situ with fluorescent fibrinogen and imaged using confocal microscopy for analysis of clot architecture in three dimensions. For each clot, we quantified the fiber resolvability, a metric of fiber distinctness or clarity, by mapping the variance of fluorescence intensity relative to background fluorescence. We also determined clot porosity by measuring the size and distribution of the gaps between fibrin fibers in three-dimensional space. We compared these measures across fibrinolysis subgroups. Fiber resolvability was significantly lower in all trauma subgroups compared with controls (n = 35 and 5, respectively; p < 0.05). We observed markedly different patterns of fibrin architecture among trauma patients stratified by fibrinolysis subgroup. Subjects with t-PA-resistant fibrinolysis shutdown exhibited abnormal, densely packed fibrin clots nearly devoid of pores. Individuals with t-PA-hypersensitive fibrinolysis shutdown had highly irregular clots with pores as large as 2500 μm to 20,000 μm, versus 78 μm to 1250 μm in noninjured controls. Fiber resolvability was significantly lower in trauma patients than controls, and subgroups of fibrinolysis differ in the porosity of the fibrin clot structure. The dense fibrin network in the t-PA-resistant group may prevent access to plasmin, suggesting a mechanism for thrombotic morbidity after injury.

Sections du résumé

BACKGROUND
Both hyperfibrinolysis and fibrinolysis shutdown can occur after severe trauma. The subgroup of trauma patients with fibrinolysis shutdown resistant to tissue plasminogen activator (t-PA)-mediated fibrinolysis have increased mortality. Fibrin polymerization and structure may influence fibrinolysis subgroups in trauma, but fibrin architecture has not been characterized in acutely injured subjects. We hypothesized that fibrin polymerization measured in situ will correlate with fibrinolysis subgroups.
METHODS
Blood samples were collected from trauma patients and noninjured controls. We selected samples across a range of fibrinolysis phenotypes (shutdown, physiologic, hyperfibrinolysis) and t-PA sensitivities (sensitive, physiologic, resistant) determined by thrombelastography. Plasma clots were created in situ with fluorescent fibrinogen and imaged using confocal microscopy for analysis of clot architecture in three dimensions. For each clot, we quantified the fiber resolvability, a metric of fiber distinctness or clarity, by mapping the variance of fluorescence intensity relative to background fluorescence. We also determined clot porosity by measuring the size and distribution of the gaps between fibrin fibers in three-dimensional space. We compared these measures across fibrinolysis subgroups.
RESULTS
Fiber resolvability was significantly lower in all trauma subgroups compared with controls (n = 35 and 5, respectively; p < 0.05). We observed markedly different patterns of fibrin architecture among trauma patients stratified by fibrinolysis subgroup. Subjects with t-PA-resistant fibrinolysis shutdown exhibited abnormal, densely packed fibrin clots nearly devoid of pores. Individuals with t-PA-hypersensitive fibrinolysis shutdown had highly irregular clots with pores as large as 2500 μm to 20,000 μm, versus 78 μm to 1250 μm in noninjured controls.
CONCLUSION
Fiber resolvability was significantly lower in trauma patients than controls, and subgroups of fibrinolysis differ in the porosity of the fibrin clot structure. The dense fibrin network in the t-PA-resistant group may prevent access to plasmin, suggesting a mechanism for thrombotic morbidity after injury.

Identifiants

pubmed: 31999655
doi: 10.1097/TA.0000000000002554
pii: 01586154-202002000-00007
pmc: PMC7546039
mid: NIHMS1624519
doi:

Substances chimiques

Biomarkers 0
Fibrin 9001-31-4
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

258-265

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM123010
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140027
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008315
Pays : United States
Organisme : NHLBI NIH HHS
ID : UM1 HL120877
Pays : United States

Références

Stroke. 2009 Apr;40(4):1499-501
pubmed: 19246700
Surgery. 2018 Sep;164(3):489-493
pubmed: 29903508
J Thromb Haemost. 2019 Jun;17(6):852-862
pubmed: 30985957
J Trauma Acute Care Surg. 2016 Jan;80(1):16-23; discussion 23-5
pubmed: 26491796
J Trauma Acute Care Surg. 2018 Jul;85(1):12-17
pubmed: 29443859
N Engl J Med. 2019 Feb 21;380(8):763-770
pubmed: 30786189
Biomed Res Int. 2017;2017:8196256
pubmed: 28740853
J Thromb Haemost. 2003 Jun;1(6):1215-9
pubmed: 12871322
J Trauma Acute Care Surg. 2017 Jan;82(1):27-34
pubmed: 27779597
Chin J Traumatol. 2017 Jun;20(3):125-132
pubmed: 28552329
J Surg Res. 2017 Dec;220:438-443
pubmed: 28755903
Ann Surg. 2016 Jun;263(6):1051-9
pubmed: 26720428
J Biomed Opt. 2013 Apr;18(4):046003
pubmed: 23552635
Blood. 2009 Nov 5;114(19):4272-8
pubmed: 19690336
J Thromb Thrombolysis. 2013 Jan;35(1):127-9
pubmed: 23080213
Thromb Res. 2016 Jul;143:130-6
pubmed: 27240111
J Trauma Acute Care Surg. 2018 Mar;84(3):426-432
pubmed: 29298240
Thromb Res. 2010 Nov;126(5):426-30
pubmed: 20813396
Thromb Haemost. 1987 Apr 7;57(2):148-53
pubmed: 3496679
J Trauma Acute Care Surg. 2017 Dec;83(6):1014-1022
pubmed: 29190254
Blood Adv. 2018 May 22;2(10):1076-1088
pubmed: 29760205
Thromb Haemost. 1996 Oct;76(4):535-40
pubmed: 8902992
Ann Surg. 1963 Jan;157:39-47
pubmed: 13952730
Shock. 2019 Mar;51(3):273-283
pubmed: 29664836
Blood Rev. 2007 May;21(3):131-42
pubmed: 17208341
Environ Int. 2016 Jul-Aug;92-93:70-6
pubmed: 27060417
Br J Anaesth. 2013 Feb;110(2):222-30
pubmed: 23112213
Thromb Haemost. 2009 Dec;102(6):1169-75
pubmed: 19967148
Thromb Res. 2014 May;133 Suppl 1:S35-7
pubmed: 24759139
J Trauma Acute Care Surg. 2014 Dec;77(6):811-7; discussion 817
pubmed: 25051384
J Trauma Acute Care Surg. 2019 Jan;86(1):20-27
pubmed: 30239375
J Am Coll Surg. 2016 Apr;222(4):347-55
pubmed: 26920989
Ann Surg. 2019 Jun;269(6):1184-1191
pubmed: 31082919
Crit Care. 2015 Mar 12;19:83
pubmed: 25880548
Transfus Apher Sci. 2008 Feb;38(1):15-23
pubmed: 18282807
Blood. 2009 Nov 26;114(23):4886-96
pubmed: 19797520
Haemophilia. 2010 May;16 Suppl 3:7-12
pubmed: 20586795

Auteurs

Nathan Dow (N)

From the Department of Surgery (N.D., Z.T.O., A.M.S., K.F.), University of Vermont, Burlington, Vermont; Ernest E Moore Shock Trauma Center at Denver Health (J.R.C., H.M., E.E.M.), University of Colorado Denver, Denver, Colorado; Department of Pharmacology (G.H., M.T.N.), University of Vermont, Burlington; and Department of Biochemistry (S.B.), University of Vermont, Colchester, Vermont.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH